MX2017014111A - Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólico. - Google Patents

Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólico.

Info

Publication number
MX2017014111A
MX2017014111A MX2017014111A MX2017014111A MX2017014111A MX 2017014111 A MX2017014111 A MX 2017014111A MX 2017014111 A MX2017014111 A MX 2017014111A MX 2017014111 A MX2017014111 A MX 2017014111A MX 2017014111 A MX2017014111 A MX 2017014111A
Authority
MX
Mexico
Prior art keywords
polypeptide
metabolic status
barrier function
intestinal barrier
gut mucosal
Prior art date
Application number
MX2017014111A
Other languages
English (en)
Inventor
Belzer Clara
Meindert De Vos Willem
Daniel CANI Patrice
Original Assignee
Univ Wageningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wageningen filed Critical Univ Wageningen
Publication of MX2017014111A publication Critical patent/MX2017014111A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Se ha encontrado que un polipéptido extracelular derivado de Akkermansia municiphila es capaz de modular y/o promover la función del sistema inmune de la mucosa intestinal y/o mantener y restaurar el estado metabólico y/o aumentar la integridad física de la barrera de la mucosa intestinal en un mamífero. El polipéptido o las células hospedadoras que comprenden dicho polipéptido pueden emplearse para prevenir y/o tratar una variedad de condiciones que se benefician de una mayor integridad física de la barrera de la mucosa intestinal y/o una función mejorada del sistema inmune de la mucosa intestinal y el estado metabólico.
MX2017014111A 2015-05-06 2016-05-04 Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólico. MX2017014111A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15166598 2015-05-06
PCT/EP2016/060033 WO2016177797A1 (en) 2015-05-06 2016-05-04 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status

Publications (1)

Publication Number Publication Date
MX2017014111A true MX2017014111A (es) 2018-02-26

Family

ID=74184294

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014111A MX2017014111A (es) 2015-05-06 2016-05-04 Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólico.

Country Status (16)

Country Link
US (2) US10738089B2 (es)
EP (1) EP3292135B1 (es)
JP (1) JP6894382B2 (es)
KR (1) KR20180011130A (es)
CN (1) CN107980043B (es)
AU (2) AU2016257315A1 (es)
BR (1) BR112017023751A2 (es)
CA (1) CA2984985A1 (es)
DK (1) DK3292135T3 (es)
EA (1) EA201700507A1 (es)
ES (1) ES2934138T3 (es)
HK (1) HK1252412A1 (es)
IL (1) IL255405B (es)
MX (1) MX2017014111A (es)
PL (1) PL3292135T3 (es)
WO (1) WO2016177797A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6868562B2 (ja) 2014-10-31 2021-05-19 ペンデュラム セラピューティクス， インコーポレイテッド 障害の微生物的処置および診断に関する方法および組成物
CN107980043B (zh) 2015-05-06 2021-09-24 瓦赫宁恩大学 多肽用于制备作用于免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的药物
EP3943093A1 (en) * 2015-09-10 2022-01-26 Université catholique de Louvain Use of pasteurized akkermansia for treating cancer
US11931400B2 (en) 2017-03-07 2024-03-19 Psomagen, Inc. Therapeutic and diagnostics compositions targeting toll-like receptors and methods thereof
WO2019018410A1 (en) * 2017-07-17 2019-01-24 The General Hospital Corporation COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
KR102340392B1 (ko) * 2018-10-08 2021-12-17 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
KR102197180B1 (ko) * 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
CN110079474B (zh) * 2019-04-12 2022-11-25 沈阳药科大学 一种高密度培养艾克曼嗜黏蛋白菌的方法
KR102263030B1 (ko) * 2019-05-07 2021-06-10 한국생명공학연구원 염증성 장질환의 예방 또는 치료용 펩타이드
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
CN110950937B (zh) * 2019-11-25 2021-05-04 安徽大学 一种改造的艾克曼菌Amuc_1100蛋白及其制备方法和应用
CN115315433A (zh) * 2020-01-10 2022-11-08 黄志宏 Tlr2交互作用的胜肽以及包括其的组合物
CN115666627A (zh) * 2020-03-25 2023-01-31 韩国生命工学研究院 源自嗜黏蛋白阿克曼菌的tars或其片段，及其用途
US20210322492A1 (en) * 2020-04-16 2021-10-21 Amucin Oy Ltd Probiotic strains and uses thereof
CN111690044B (zh) * 2020-05-06 2022-03-01 中南大学湘雅二医院 Amuc1100蛋白的用途
EP4175975A1 (en) 2020-07-01 2023-05-10 Wageningen Universiteit Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
WO2022098051A1 (ko) * 2020-11-05 2022-05-12 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
CN113413466B (zh) * 2020-12-15 2022-08-19 和度生物医药(上海)有限公司 用于治疗癌症的amuc_1100和免疫检查点调节剂的组合疗法
CN117304264B (zh) * 2023-11-27 2024-02-06 中国科学院烟台海岸带研究所 一种具有肠屏障保护功能的五肽rp5及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
EP1374672B8 (en) * 2001-02-28 2009-11-04 National Institute of Advanced Industrial Science and Technology Drosophila strain carrying bradeion gene(s) transferred thereinto
US20060094649A1 (en) * 2002-12-10 2006-05-04 Keogh Elissa A Hla-a1,-a2,-a3,-a24,-b7, and-b44 tumor associated antigen peptides and compositions
WO2004069156A2 (en) 2003-01-30 2004-08-19 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
US20050163764A1 (en) 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
WO2008028117A2 (en) 2006-08-31 2008-03-06 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
CA2761573A1 (en) 2009-05-11 2010-11-18 Nestec S.A. Bifidobacterium longum ncc2705 (cncm i-2618) and immune disorders
WO2011137369A1 (en) * 2010-04-29 2011-11-03 The Regents Of The University Of California Production of gamma-aminobutyric acid by recombinant microorganisms
US9104670B2 (en) 2010-07-21 2015-08-11 Apple Inc. Customized search or acquisition of digital media assets
WO2012052868A2 (en) 2010-10-20 2012-04-26 Koninklijke Philips Electronics N.V. Disaggregation apparatus
EP2449891A1 (en) 2010-11-05 2012-05-09 Nestec S.A. Drinking yoghurt preparations containing non-replicating probiotic micro-organisms
ES2565407T3 (es) 2010-11-05 2016-04-04 Nestec S.A. Procedimiento para la preparación de un producto alimenticio para animales de compañía, el cual contiene microorganismos probióticos
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
KR101740893B1 (ko) * 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
CN107980043B (zh) 2015-05-06 2021-09-24 瓦赫宁恩大学 多肽用于制备作用于免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的药物
EP3943093A1 (en) 2015-09-10 2022-01-26 Université catholique de Louvain Use of pasteurized akkermansia for treating cancer
US11071626B2 (en) 2018-03-16 2021-07-27 W. L. Gore & Associates, Inc. Diametric expansion features for prosthetic valves

Also Published As

Publication number Publication date
CN107980043A (zh) 2018-05-01
US20210147489A1 (en) 2021-05-20
HK1252412A1 (zh) 2019-05-24
JP2018515502A (ja) 2018-06-14
AU2016257315A1 (en) 2017-11-23
AU2020267210B2 (en) 2023-10-12
DK3292135T3 (da) 2022-10-31
JP6894382B2 (ja) 2021-06-30
ES2934138T3 (es) 2023-02-17
US11466057B2 (en) 2022-10-11
KR20180011130A (ko) 2018-01-31
US10738089B2 (en) 2020-08-11
PL3292135T3 (pl) 2023-01-02
CA2984985A1 (en) 2016-11-10
CN107980043B (zh) 2021-09-24
EP3292135A1 (en) 2018-03-14
WO2016177797A1 (en) 2016-11-10
AU2020267210A1 (en) 2020-12-17
IL255405B (en) 2022-01-01
US20180265554A1 (en) 2018-09-20
IL255405A0 (en) 2017-12-31
EP3292135B1 (en) 2022-09-21
BR112017023751A2 (pt) 2018-07-31
EA201700507A1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
MX2017014111A (es) Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólico.
MX2017008449A (es) Polipeptido de pirina y modulacion inmune.
ZA201805385B (en) Computer security based on artificial intelligence
IL256563B (en) Computer security systems and methods using asynchronous introspection exceptions
EP3262559A4 (en) System and method to mitigate malware
HUE048956T2 (hu) Kijelzõbe integrált felhasználóosztályozó-, biztonsági- és ujjlenyomat-olvasó rendszer
EP3166675A4 (en) Facial access oxygen face mask and component system
BR112017006664A2 (pt) terapias de combinação
MD4801C1 (ro) Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
GB201617037D0 (en) Management of group-sourced contacts directories, systems and methods
GB2559275B (en) Methods and systems for performing actions based on biometric data
PH12015501983A1 (en) Peptides and compositions for treatment of joint damage
EP3167359A4 (en) USING INDIVIDUALIZED APIs TO BLOCK AUTOMATED ATTACKS ON NATIVE APPS AND/OR PURPOSELY EXPOSED APIs
IL257040B (en) Systems and processes for executing private programs on untrusted computers
MX2015016356A (es) Localizacion de dispositivo utilizando camara y señal inalambrica.
GB2542967B (en) Improvements to halocarbon recycling methods and systems
IL262894B (en) Using hardware based secure isolated region to prevent piracy and cheating on electronic devices
HK1215609A1 (zh) 保護嵌入式管理程序系統中的重要數據結構
AU362020S (en) Medical device control unit
MX2016014050A (es) Combinacion de un acido hialuronico y un polisacarido sulfatado.
IL247551B (en) A peptide drug in the form of a dry powder
DK3808188T1 (da) Fiskefoder og fremgangsmåde til smoltifikation og forebyggelse af desmoltifikation hos salmonidae samt til profylakse og behandling af hæmoragisk smoltsyndrom (hss) hos salmonidae
EP3157215A4 (en) Interface circuit and information processing system
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
ZA201800705B (en) Fowl adenovirus 9 (fadv-9) vector system and associated methods